Michael Zelefsky, MD, presented “Precision Radiation Therapy: Low- to Intermediate-Risk Prostate Cancer” during the 4th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on October 3, 2019 in Boston, Massachusetts.
How to cite: Zelefsky, Michael. “Precision Radiation Therapy: Low- to Intermediate-Risk Prostate Cancer” October 3, 2019. Accessed Nov 2024. https://dev.grandroundsinurology.com/precision-radiation-therapy-low-to-intermediate-risk-prostate-cancer/
Precision Radiation Therapy: Low- to Intermediate-Risk Prostate Cancer – Summary:
Michael Zelefsky, MD, discusses the need for advances in molecular imaging and radiomics and for integrating these techniques with precision radiation therapy in order to improve selective dose delivery for low- and intermediate-risk prostate cancer patients. He describes evolving methods of radiation delivery, dose planning, reducing radiation exposure to normal tissues, and delineation of the dominant intraprostatic lesion in this era of dose-escalation.
About The 4th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer:
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a multi-day, multi-disciplinary forum designated to informing health care stakeholders about topics including in-vitro fluid- and tissue-based molecular diagnostics, novel observation strategies such as active surveillance, and novel therapeutic interventions. Along with this forum’s efforts to form a consensus on the future of prostate diagnostics and precision care, it aims to create an educational and research strategy for its realization. Dr. Zelefsky presented this lecture during the 4th iteration of this Summit in 2019.
ABOUT THE AUTHOR
Michael J. Zelefsky, MD, is a board-certified radiation oncologist and co-leader of Memorial Sloan Kettering’s Genitourinary Disease Management Team, a multidisciplinary group of physicians who work together to treat patients with urologic malignancies. As a recognized expert in the field of radiation therapy, he is Chief of Memorial Sloan Kettering’s Brachytherapy Service.
The prostate brachytherapy program at Memorial Sloan Kettering, which Dr. Zelefsky helped develop and enhance since joining the staff in 1990, is known for its depth of experience and cutting-edge approach in treating men with prostate cancer. For patients with advanced or aggressive prostate cancer, he has significant expertise using high-dose-rate brachytherapy and temporary brachytherapy, in which patients receive several high-dose treatments either as a boost or as the sole treatment. Dr. Zelefsky also has experience using brachytherapy in patients whose tumor has recurred after external-beam radiation therapy or seed implant, as well as expertise using image-guided stereotactic radiosurgery for areas of metastases (spread) such as bone or lymph nodes.
In addition, Dr. Zelefsky was instrumental in pioneering the use of IMRT (intensity-modulated radiation therapy, which is computer-guided delivery of high doses of radiation directly to the tumor) and IGRT (image-guided radiotherapy, radiation beams targeted precisely to the tumor) for treating men with prostate cancer. He is Editor-in-Chief of Brachytherapy, a medical journal that addresses all aspects of this sub-specialty, and Chairman of the National Patterns of Care Study for Genitourinary Cancers. He is also a past president of the American Brachytherapy Society.
For his work in this field, Dr. Zelefsky has been honored to receive several awards including the Boyer Award for Excellence in Clinical research, the Outstanding Teaching Award in the Department of Radiation Oncology at Memorial Sloan Kettering, the 2009 Henschke Medal (the highest award of the American Brachytherapy Society for achievements in Brachytherapy), and the 2009 Emanuel Van Descheuren Award for Excellence in Translational Research.
